Vanguard Group Inc Relmada Therapeutics, Inc. Transaction History
Vanguard Group Inc
- $5.97 Trillion
- Q2 2025
A detailed history of Vanguard Group Inc transactions in Relmada Therapeutics, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 364,077 shares of RLMD stock, worth $844,658. This represents 0.0% of its overall portfolio holdings.
Number of Shares
364,077
Previous 1,208,075
69.86%
Holding current value
$844,658
Previous $326,000
33.13%
% of portfolio
0.0%
Previous 0.0%
Shares
13 transactions
Others Institutions Holding RLMD
# of Institutions
55Shares Held
5.43MCall Options Held
0Put Options Held
0-
Driehaus Capital Management LLC Chicago, IL740KShares$1.72 Million0.0% of portfolio
-
Acadian Asset Management LLC Boston, MA619KShares$1.44 Million0.0% of portfolio
-
Black Rock Inc. New York, NY573KShares$1.33 Million0.0% of portfolio
-
Advisor Shares Investments LLC Bethesda, MD397KShares$919,9120.04% of portfolio
-
Geode Capital Management, LLC Boston, MA302KShares$701,4610.0% of portfolio
About RELMADA THERAPEUTICS, INC.
- Ticker RLMD
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 28,608,500
- Market Cap $66.4M
- Description
- Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that ...